{
  "id": 4850762,
  "title": "Piper Sandler upgrades Tempus AI stock rating on acquisition benefits",
  "url": "https://urgent.news/2026/09/01/piper-sandler-upgrades-tempus-ai-stock-rating-on-acquisition-benefits",
  "topic": "ai",
  "section": "AI",
  "published": "2026-09-01T11:18:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-upgrades-tempus-ai-stock-rating-on-acquisition-benefits-93CH-4883849"
  },
  "original_language": "en",
  "account": "Piper Sandler raised its rating on Tempus AI Inc (NASDAQ: TEM) to Overweight from Neutral on Monday, also increasing its price target to $76 from $56. This implies a potential 20% upside from the current trading price of $63.05. Analysts have price targets ranging from $35 to $100, which reflects varying opinions on the company's $11.4 billion market valuation. The upgrade comes after the pending acquisition of Personalis, which will provide Tempus with a unique tumor-informed MRD platform. The firm highlighted that the positive INTerpath-001 readout increases the strategic value of both companies as the leading provider of tumor sequencing for a potentially new therapeutic class. Tempus AI has shown strong growth, with a 50% revenue increase over the last year. While 6 analysts have revised their earnings estimates upward for the upcoming period, the stock may be slightly overvalued according to the platform's Fair Value analysis. The FDA approval of the tumor-only xT CDx test is a significant milestone for Tempus, which will allow it to pursue unified ADLT pricing for xT, potentially followed by the xF product in the second half of 2027.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}